XML 46 R23.htm IDEA: XBRL DOCUMENT
v2.4.1.9

The Company and Summary of Significant Accounting Policies (Details) (USD $) | 0 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended
--- | --- | --- | --- | ---
Mar. 04, 2013 | Dec. 31, 2014 Segment | Dec. 31, 2013 | Feb. 18, 2015 | Feb. 03, 2014 | Jan. 31, 2013 | Feb. 28, 2014
Company Basis of Presentation (Textual) [Abstract] |  |  |  |  |  |  |
Date of completion of business combination with Nuvelo |  | Jan. 27, 2009 |  |  |  |  |
Revenues |  | $ 0 us-gaap_Revenues |  |  |  |  |
Fund raised through sale of convertible preferred and common stock |  |  | 19,300,000 us-gaap_ProceedsFromIssuanceOrSaleOfEquity |  |  |  |
Proceeds from the issuance of common stock |  | 9,038,000 us-gaap_ProceedsFromIssuanceOfCommonStock | 1,741,000 us-gaap_ProceedsFromIssuanceOfCommonStock |  |  |  |
Notification for delisting of shares |  | On February 18, 2015, we received notification from NASDAQ of potential delisting of our shares from the NASDAQ Capital Market because the closing bid price of our common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30 days. NASDAQ rules provided us a 180 calendar day grace period from the date of the Notice to regain compliance by meeting the continued listing standard. The continued listing standard would be met if our common stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period. |  |  |  |  |
Reverse stock split | 1-for-6 reverse split |  |  |  |  |  |
Concentrations of credit risk |  | 0 us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure |  |  |  |  |
Number of segments |  | 1 us-gaap_NumberOfOperatingSegments |  |  |  |  |
Subsequent Event |  |  |  |  |  |  |
Company Basis of Presentation (Textual) [Abstract] |  |  |  |  |  |  |
Minimum closing bid price of common stock |  |  |  | $ 1.00 abio_ClosingBidPriceOfCommonStock / us-gaap_SubsequentEventTypeAxis = us-gaap_SubsequentEventMember |  |  |
Number of grace days provided by NASDAQ to meet continued listing standard |  |  |  | 180 days |  |  |
Registered Direct Offering |  |  |  |  |  |  |
Company Basis of Presentation (Textual) [Abstract] |  |  |  |  |  |  |
Proceeds from the issuance of common stock |  |  |  |  | $ 8,700,000 us-gaap_ProceedsFromIssuanceOfCommonStock / us-gaap_SubsidiarySaleOfStockAxis = abio_RegisteredDirectOfferingMember | $ 730,000 us-gaap_ProceedsFromIssuanceOfCommonStock / us-gaap_SubsidiarySaleOfStockAxis = abio_RegisteredDirectOfferingMember | $ 7,900,000 us-gaap_ProceedsFromIssuanceOfCommonStock / us-gaap_SubsidiarySaleOfStockAxis = abio_RegisteredDirectOfferingMember
Phase 3 heart failure (HF) trial of Gencaro | BEST Trial |  |  |  |  |  |  |
Company Basis of Presentation (Textual) [Abstract] |  |  |  |  |  |  |
Number of patients |  | 2,708 abio_NumberOfPatients / abio_ClinicalTrialsByPhaseAxis = abio_PhaseThreeHeartFailureMember / us-gaap_HealthCareTrustFundAxis = abio_BestTrialMember |  |  |  |  |
Phase 3 heart failure (HF) trial of Gencaro | GENETIC-AF Trial |  |  |  |  |  |  |
Company Basis of Presentation (Textual) [Abstract] |  |  |  |  |  |  |
Number of patients company plans to enroll |  | 420 abio_NumberOfPatientsCompanyPlansToEnroll / abio_ClinicalTrialsByPhaseAxis = abio_PhaseThreeHeartFailureMember / us-gaap_HealthCareTrustFundAxis = abio_GENETICAFTrialMember |  |  |  |  |
Phase Two B Heart Failure | GENETIC-AF Trial |  |  |  |  |  |  |
Company Basis of Presentation (Textual) [Abstract] |  |  |  |  |  |  |
Number of patients company plans to enroll |  | 200 abio_NumberOfPatientsCompanyPlansToEnroll / abio_ClinicalTrialsByPhaseAxis = abio_PhaseTwoBHeartFailureMember / us-gaap_HealthCareTrustFundAxis = abio_GENETICAFTrialMember |  |  |  |  |
Original |  |  |  |  |  |  |
Company Basis of Presentation (Textual) [Abstract] |  |  |  |  |  |  |
Business combination with Nuvelo, date of agreement |  | Sep. 24, 2008 |  |  |  |  |
Amendment |  |  |  |  |  |  |
Company Basis of Presentation (Textual) [Abstract] |  |  |  |  |  |  |
Business combination with Nuvelo, date of agreement |  | Oct. 28, 2008 |  |  |  |  |

X
- Definition Closing bid price of common stock. + References No definition available. + Details
Name: | abio_ClosingBidPriceOfCommonStock
Namespace Prefix: | abio_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | abio_CompanyBasisOfPresentationTextualAbstract
Namespace Prefix: | abio_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Grace period provided to meet continued listing standard. + References No definition available. + Details
Name: | abio_GracePeriodProvidedToMeetContinuedListingStandard
Namespace Prefix: | abio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Notification for delisting of shares description. + References No definition available. + Details
Name: | abio_NotificationForDelistingOfSharesDescription
Namespace Prefix: | abio_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of patients. + References No definition available. + Details
Name: | abio_NumberOfPatients
Namespace Prefix: | abio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of patients company plans to enroll. + References No definition available. + Details
Name: | abio_NumberOfPatientsCompanyPlansToEnroll
Namespace Prefix: | abio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Date when the business acquisition agreement was executed, in CCYY-MM-DD format. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Date when the acquirer obtains control of the acquiree, in CCYY-MM-DD format. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=34752592&loc=d3e845-128460 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Acquisition Date -URI http://asc.fasb.org/extlink&oid=6919109 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=34752592&loc=d3e848-128460 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611 + Details
Name: | us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References No definition available. + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOrSaleOfEquity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C + Details
Name: | us-gaap_StockholdersEquityReverseStockSplit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | abio_ClinicalTrialsByPhaseAxis=abio_PhaseThreeHeartFailureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | abio_ClinicalTrialsByPhaseAxis=abio_PhaseTwoBHeartFailureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=abio_AmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=abio_OriginalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=abio_RegisteredDirectOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |